Aurobindo Pharma

Financial Highlights - Consolidated

Rs. Million
Profit and Loss Account	FY23-24	FY22-23	FY21-22	FY20-21	FY19-20	FY18-19	FY17-18	FY16-17	FY15-16
Net sales/income from operations (Net of excise duty)	287,045	246,171	233,666	245,579	227,380	192,259	162,329	148,448	137,097
Other operating income	2,974	2,383	889	2,167	3,606	3,376	2,670	2,451	2,455
Total income from operations (net)	290,019	248,554	234,555	247,746	230,985	195,636	164,998	150,899	139,552
Expenses
Cost of material consumed	107,761	96,525	73,718	83,173	77,250	74,450	56,294	51,849	48,256
Purchase of stock-in-trade	27,729	20,504	19,518	23,154	21,121	19,432	16,059	15,585	14,294
Changes in inventories of finished goods, work-in-progress and stock-in-trade	-9,462	-4,097	8,167	-7,302	-1,019	-6,756	-4,825	-3,092	-929
Employee benefits expense	39,229	35,223	34,509	35,350	32,192	25,849	21,308	17,678	15,426
Other expenses	66,330	62,817	54,775	60,037	52,798	43,141	38,277	34,536	30,624
Total expenses	231,589	210,972	190,687	194,412	182,342	156,116	127,113	116,556	107,671
EBITDA	58,430	37,582	43,868	53,334	48,643	39,519	37,885	34,343	31,881
Depreciation and Amortisation expense	15,217	12,446	11,265	10,554	9,667	6,680	5,580	4,276	3,924
Profit/(Loss) from operations before other income, finance costs, foreign exchange (gain)/loss and exceptional items	43,213	25,136	32,603	42,780	38,976	32,840	32,306	30,067	27,958
Other Income	5,186	2,906	2,504	2,773	862	1,157	1,020	538	701
Finance costs	2,897	1,405	486	745	1,598	1,627	777	667	927
Foreign exchange (Gain)/Loss	-388	396	-700	-1,036	397	603	168	-621	304
Profit/(Loss) from ordinary activities before exceptional items	45,890	26,242	35,320	45,844	37,843	31,767	32,381	30,558	27,429
Exceptional item	1,919	0	1,280	-28,146	261	881	-	-	-
Profit Before Tax	43,972	26,242	34,040	73,990	37,582	30,887	32,381	30,558	27,429
Tax expense/(credit)	12,110	6,849	7,256	20,098	9,135	7,269	8,183	7,597	7,207
Net Profit /(Loss)	31,861	19,393	26,784	53,892	28,447	23,618	24,198	22,962	20,221
Minority Interest & Share of profit/(loss) of JV	-132	-118	-302	-543	166	29	-34	-55	-30
Net Profit/(Loss) after minority interest	31,730	19,275	26,482	53,348	28,281	23,647	24,232	23,017	20,251
Abridged Balance Sheet	FY23-24	FY22-23	FY21-22	FY20-21	FY19-20	FY18-19	FY17-18	FY16-17	FY15-16
EQUITY AND LIABILITIES
Share Capital	586	586	586	586	586	586	586	586	586
Reserve & Surplus	297,842	267,813	245,174	218,713	167,518	138,322	166,218	91,133	72,288
Minority Interest	80	120	-19	-9	1	16	18	21	26
Long term Borrowings	21,349	6,190	2,492	1,684	0	1,800	4,512	1,814	7,428
Short term Borrowings	41,803	42,426	21,236	48,027	54,223	65,732	40,313	29,027	36,727
Deferred tax Liabilities (Net)	3,566	3,896	4,110	5,746	3,025	2,813	2,353	493	240
Current Liabilities & Provisions	85,489	77,870	65,639	63,793	63,911	55,276	47,051	37,420	41,909
Total	450,715	398,900	339,217	338,540	289,263	264,544	211,010	162,494	159,202
ASSETS
Tangible Assets and Capital Work in progress	142,849	124,918	106,660	93,155	81,166	70,356	61,361	53,204	42,163
Intangible Assets (Inc. Goodwill)	40,766	39,219	36,133	31,196	32,658	31,077	19,676	9,715	8,115
Non-current Investments	3,217	3,917	6,183	4,312	5,547	3,602	3,115	2,459	1,229
Deferred Tax Assets (Net)	12,126	6,775	2,886	4,527	1,632	1,833	1,588	1,678	2,063
Loans and Advances	1,488	3,349	1,268	3,163	1,893	1,146	798	1,090	1,258
Other non-current Assets	8,342	5,389	4,987	4,095	2,379	2,885	2,635	2,288	1,430
Current Assets	241,928	215,332	181,100	198,092	163,988	153,645	121,878	92,062	102,944
Total	450,715	398,900	339,217	338,540	289,263	264,544	211,010	162,494	159,202

All Numbers are as per IND AS

Investors

Financial Highlights - Consolidated